BDNF Release and Signaling are Required for the Antidepressant Actions of GLYX-13

Conventional antidepressant medications, which act on monoaminergic systems, display significant limitations, including a time lag of weeks to months and low rates of therapeutic efficacy. GLYX-13 is a novel glutamatergic compound that acts as an NMDA modulator with glycine-like partial agonist prop...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Psychiatry
Asıl Yazarlar: Kato, Taro, Fogaça, Manoela V., Deyama, Satoshi, Li, Xiao-Yuan, Fukumoto, Kenichi, Duman, Ronald S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5988860/
https://ncbi.nlm.nih.gov/pubmed/29203848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mp.2017.220
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller